Validation of the postoperative prognostication tool PREDICT version 2.2 and 3.0 using data from the National cancer center hospital in Japan

Despite these differences, both versions demonstrated satisfactory performance, suggesting that they can be generalized for Japanese patients with postoperative breast cancer. Notably, v3.0, given its improved calibration, might be more suitable for supporting shared decision making. The model's performance in predicting 5-year OS supports its generalizability, whereas 10-year projections warrant caution due to limited follow-up. Overall, this study demonstrates that PREDICT is a valuable prognostic tool for Japanese patients with breast cancer.